[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bicara Therapeutics Inc (BCAX)

Bicara Therapeutics Inc (BCAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,905,416
  • Shares Outstanding, K 65,704
  • Annual Sales, $ 0 K
  • Annual Income, $ -137,950 K
  • EBIT $ -174 M
  • EBITDA $ -174 M
  • 60-Month Beta -0.81
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.69

Options Overview Details

View History
  • Implied Volatility 75.27% (-2.82%)
  • Historical Volatility 45.30%
  • IV Percentile 3%
  • IV Rank 15.15%
  • IV High 321.03% on 09/26/25
  • IV Low 31.38% on 09/08/25
  • Expected Move (DTE 14) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 2.41
  • Today's Open Interest 3,058
  • Open Int (30-Day) 3,896
  • Expected Range 29.00 to 29.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.80
  • Number of Estimates 6
  • High Estimate $-0.51
  • Low Estimate $-0.97
  • Prior Year $-0.50
  • Growth Rate Est. (year over year) -60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.09 +51.91%
on 06/03/26
29.90 -3.01%
on 07/01/26
+9.36 (+47.66%)
since 06/02/26
3-Month
18.62 +55.75%
on 05/19/26
29.90 -3.01%
on 07/01/26
+7.53 (+35.07%)
since 04/02/26
52-Week
8.74 +231.81%
on 07/07/25
29.90 -3.01%
on 07/01/26
+19.80 (+215.22%)
since 07/02/25

Most Recent Stories

More News
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 29.00 (+0.31%)
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the...

BCAX : 29.00 (+0.31%)
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

    At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective...

BCAX : 29.00 (+0.31%)
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy...

BCAX : 29.00 (+0.31%)
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 29.00 (+0.31%)
Bicara Therapeutics Q1 Earnings Call Highlights

Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while...

BCAX : 29.00 (+0.31%)
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up...

BCAX : 29.00 (+0.31%)
BCAX's Phase Three Timeline Meets the Market's Patience Threshold

Barchart Research What to Expect from BCAX Earnings BCAX Generated May 8, 2026 Current Price $22.58 EPS Estimate $$-0.64 Consensus Rating Strong Buy Average Move 5.17% BCAX's Phase Three Timeline Meets...

BCAX : 29.00 (+0.31%)
BCAX's Phase Three Timeline Meets the Market's Patience Threshold

Barchart Research What to Expect from BCAX Earnings BCAX Generated May 8, 2026 Current Price $22.58 EPS Estimate $$-0.64 Consensus Rating Strong Buy Average Move 5.17% BCAX's Phase Three Timeline Meets...

BCAX : 29.00 (+0.31%)
BCAX's Phase Three Timeline Meets the Market's Patience Threshold

Barchart Research What to Expect from BCAX Earnings BCAX Generated May 8, 2026 Current Price $22.58 EPS Estimate $$-0.64 Consensus Rating Strong Buy Average Move 5.17% BCAX's Phase Three Timeline Meets...

BCAX : 29.00 (+0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. The company's lead asset includes ficerafusp alfa. Bicara Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 30.77
2nd Resistance Point 30.27
1st Resistance Point 29.64
Last Price 29.00
1st Support Level 28.51
2nd Support Level 28.01
3rd Support Level 27.38

See More

52-Week High 29.90
Last Price 29.00
Fibonacci 61.8% 21.82
Fibonacci 50% 19.32
Fibonacci 38.2% 16.82
52-Week Low 8.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.